Search
CNS Pharmaceuticals Inc
CNSPAdd to Watchlist
5.070USD
+0.390+8.33%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
4.11MMarket Cap
LossP/E TTM
More Details of CNS Pharmaceuticals Inc Company
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
CNS Pharmaceuticals Inc Info
Ticker SymbolCNSP
Company nameCNS Pharmaceuticals Inc
IPO dateNov 08, 2019
CEOClimaco (John Michael)
Number of employees4
Security typeOrdinary Share
Fiscal year-endNov 08
Address2100 West Loop S Ste 900
CityHOUSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77027-3522
Phone18009469185
Websitehttps://cnspharma.com/
Ticker SymbolCNSP
IPO dateNov 08, 2019
CEOClimaco (John Michael)
Company Executives of CNS Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
11.00
+54.55%
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Jeffry R. (Jeff) Keyes
Mr. Jeffry R. (Jeff) Keyes
Independent Director
Independent Director
--
-100.00%
Mr. Carl Evans
Mr. Carl Evans
Independent Director
Independent Director
--
--
Ms. Faith L. Charles, J.D.
Ms. Faith L. Charles, J.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Dr. Bettina M. Cockroft, M.D.
Dr. Bettina M. Cockroft, M.D.
Independent Director
Independent Director
--
-100.00%
Ms. Amy Mahery
Ms. Amy Mahery
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Chief Executive Officer, Director
Chief Executive Officer, Director
11.00
+54.55%
Mr. Christopher S. Downs, CPA
Mr. Christopher S. Downs, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sandra L. Silberman, M.D., Ph.D.
Dr. Sandra L. Silberman, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Science Officer
Chief Science Officer
--
--
Dr. Jerzy (George) Gumulka, Ph.D.
Dr. Jerzy (George) Gumulka, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Jeffry R. (Jeff) Keyes
Mr. Jeffry R. (Jeff) Keyes
Independent Director
Independent Director
--
-100.00%
FAQs
Who are the top five shareholders of CNS Pharmaceuticals Inc?
The top five shareholders of CNS Pharmaceuticals Inc are: Mr. John Michael Climaco, Esq.
How many institutions hold shares of CNS Pharmaceuticals Inc (CNSP)?
As of 2026Q1, 37 institutions hold shares of CNS Pharmaceuticals Inc, with a combined market value of approximately 147.22K, accounting for 18.14% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 57672.00.